Women's Health: Epithelial Ovarian Cancer

IN THIS ARTICLE

Symptoms and diagnosis

Surgical options

Drug treatments

The Doctor's Health Tip

Even small amounts of caffeine in some at-risk individuals can precipitate or exaggerate anxiety. more...

Epithelial Ovarian Cancer

Renata Urban, M.D., and Jonathan S. Berek, M.D., M.M.S.

Dr. Urban is a Resident and Dr. Berek is Professor and Chair, Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford, CA.

Ovarian cancer is the most lethal of all cancers that affect only women. Because it is so rarely discovered before it has reached an advanced stage, it is both difficult to treat and difficult to deal with for patients and their families. Detecting early-stage ovarian cancer has proven to be a challenge that modern technology, even high-tech screening methods, have not been able to meet. The vast majority of ovarian tumors begin in the ovarian epithelium, a type of tissue that forms the surface of the ovaries. By the time most women seek treatment for epithelial ovarian cancer, the disease has already reached an advanced stage, despite the fact that they usually have no more than mild, vague symptoms. Upon diagnosis, the usual next step is surgery to remove all visible tumors, followed by chemotherapy. If the disease is particularly advanced, it may be treated with either intravenous (delivered into the blood through an IV) or intraperitoneal (placed directly inside the abdomen) chemotherapy.

Who Gets Epithelial Ovarian Cancer?

The Odds
A contemporary American woman's lifetime risk of developing ovarian cancer is approximately 1 in 70.¹ In 2008, an estimated 21,650 women will be diagnosed with ovarian cancer and 15,520 will die from the disease.²

Risk Factors

Menopause
Most epithelial ovarian tumors occur in women who are between 56 and 60 and have experienced the physical and hormonal changes of menopause. Nearly 30% of ovarian masses in women who are past menopause are malignant (cancerous), while only 7% are malignant in women of reproductive age.³

Patterns of Fertility
Ovarian cancer is also related to fertility.⁴ Early sexual maturity and late menopause both increase a woman's statistical risk of ovarian cancer.⁵

Fertility Drugs, but Not Birth Control
Some have speculated that fertility drugs increase the risk of ovarian cancer, though several studies have found otherwise.^6,7 One meta-analysis, however, showed that a period of infertility lasting greater than five years was associated with an increased risk of ovarian cancer.⁸ Taking birth control pills helps protect women against the development of ovarian cancer, with the benefit lasting as long as 15 years after the pill is discontinued.⁹

Obesity
Obesity is another risk factor for ovarian cancer.^10,11

Germline Mutations
Nearly 90% of ovarian tumors are sporadic; that is, they have no genetic cause; however, in 5-10% of ovarian malignancies there are genetic mutations.^12,13 Two of these genetic mutations, called BRCA-1 and BRCA-2, are more common in women of Ashkenazi Jewish descent. Women who carry the BRCA-1 mutation have been estimated to have a lifetime risk for ovarian cancer of between 28-44%, and for women with a BRCA-2 mutation, the risk has been estimated as high as 27%.¹⁴ In women with a mutation in either the BRCA-1 or BRCA-2 gene, the use of oral contraceptives seems to have a protective effect.¹⁵ Furthermore, a recent study of 1,828 women with a BRCA-1 or BRCA-2 mutation found that having a preventive bilateral salpingooophorectomy -- a surgical operation that removes the Fallopian tubes and ovaries -- reduced cancer risk by 80%.¹⁶

Symptoms and Diagnosis
Most women with ovarian cancer experience some symptoms; unfortunately, as mentioned above, these symptoms tend to be mild and vague. A 2000 survey of 1,725 women with ovarian cancer revealed that 95% of women had symptoms before being diagnosed; interestingly, 89% of those with early stage disease reported symptoms.¹⁷ These symptoms include bloating, urinary symptoms and increased abdominal size.¹⁸ Urinary frequency or constipation may be caused by compression of the bladder or rectum by an ovarian tumor.

In the advanced stage of the disease, typical symptoms include abdominal distension, nausea, anorexia or a premature feeling of fullness when eating.^19,20 One of the most important signs of ovarian cancer is the presence of an unusual mass near the pelvis. A mass that is solid, irregularly shaped or fixed in the pelvis is suspicious for cancer. An upper abdominal mass or ascites (excess fluid in the abdomen) is an almost certain sign of ovarian cancer. Unfortunately, these can be hard to detect in a physical exam, especially with obese women.²¹

In a women with a mass in the adnexa, (the area including the ovaries and Fallopian tubes), an ultrasound is usually performed before surgery.^{22,23,24,25,26} Various tests are used to determine if an adnexal mass is benign or malignant.^{27,28,29,30,31,32,33,34,35}

Recently, proteomics -- the study of an organism's full complement of proteins -- has been suggested as a way to screen for ovarian cancer, but studies have been inconclusive.^36,37,38

Before doctors operate on a woman suspected of having ovarian cancer, they must first eliminate a number of other disorders and diseases, including other cancers that might have metastasized into the ovary. Any woman with evidence of intestinal obstruction should undergo a colonoscopy. If there are any symptoms of disease in the upper gastrointestinal tract, an endoscopy should be done.

Women with breast masses should have bilateral mammography performed, because breast cancer can rarely metastatize to the ovaries. If there is fluid buildup in the abdomen, but no pelvic mass, a CT scan or MRI of the abdomen and pelvic area should be done to look for other kinds of tumors.³⁹

Surgery and Ovarian Cancer
Epithelial ovarian malignancies are classified by stages, according to the 2002 revised American Joint Committee on Cancer (AJCC) and the International Federation of Gynecologic and Obstetrics (FIGO) system, which is shown below (Table 1). This is fairly technical; if you or a loved one is being treated for ovarian cancer and you have questions about these stagings, you should discuss them with your physician. The majority of patients (58-63%) who are diagnosed with ovarian cancer have stage III-IV disease.⁴⁰

Table 1. FIGO Staging.

Stage I
Growth limited to the ovaries.

Stage IA
Growth limited to one ovary, no ascites, or abnormal intraabdominal fluid, containing malignant cells. No tumor on the external ovarian surface, ovarian capsule intact.

Stage IB
Growth involving both ovaries, no ascites containing malignant cells, no tumor on the external surface, capsule intact.

Stage IC
Tumor either stage IA or IB but with tumor on the surface on one or both ovaries; or with capsule ruptured; or with ascites present containing malignant cells.

Stage II
Growth involving one or both ovaries with pelvic extension.

Stage IIA
Extension and/or metastases to the uterus and/or tubes.

Stage IIB
Extension to other pelvic tissues.

Stage IIC
Tumor either stage IIA or IIB, but with tumor on the surface of one or both ovaries; or with capsule(s) ruptured; or with ascites present containing malignant cells or with positive peritoneal washings.

Stage III
Tumor involving one or both ovaries with peritoneal implants outside the pelvis and/or positive retroperitoneal or inguinal lymph nodes. Superficial liver metastases equals stage III. Tumor is limited to the true pelvis, but with histology proves malignant extension to small bowel or omentum.

Stage IIIA
Tumor grossly limited to the true pelvis with negative nodes but with histologically confirmed microscopic seeding of abdominal peritoneal surfaces.

Stage IIIB
Tumor of one or both ovaries with histologically confirmed implants of abdominal peritoneal surfaces, none exceeding 2 cm in diameter. Nodes negative.

Stage IIIC
Abdominal implants >2 cm in diameter and/or positive retroperitoneal or inguinal nodes.

Stage IV
Growth involving one or both ovaries with distant metastasis.^41,42,43

Surgery for ovarian cancer is normally done as follows:

Performance of a laparotomy, or surgical incision in the abdomen
Removal of free fluid to be analyzed for the presence of cancerous cells; if no free fluid is present, washing should be obtained by placing saline solution in the pelvic cul-de-sacs and gutters
Total hysterectomy and bilateral salpingooophorectomy (removal of all ovaries and Fallopian tubes)
Exploration of all intraabdominal and peritoneal surfaces, with biopsies of suspicious lesions
Assessment of the pelvic and paraaortic lymph nodes with removal of lymph nodes that might be cancerous.
Physical examination of the diaphragm, liver and spleen
Removal of the omentum, which is a piece of tissue that hangs below the stomach.
Appendectomy.^44,45

In young women with early stage disease, a more conservative approach may be undertaken that spares an unaffected ovary and uterus. However, the uterus and ovary will need to be removed once childbearing is completed.

Treatment
The technique for surgical staging centers on removal of all malignant cells. This principle is based on studies that have shown an improved outcome for patients with less than 1 cm of disease after surgical staging.^41,42 Thorough surgical staging is crucial to the management of patients with ovarian cancer, as postoperative therapy and prognosis will depend on the surgical stage. In a study of 100 patients who were initially thought to have early stage disease, a second surgical procedure revealed that 31% had advanced stage disease.⁴³

After surgery, most women with epithelial ovarian cancer will be given chemotherapy (carboplatin and paclitaxel).^53,54

Table 2. Combination Chemotherapy for Advanced Epithelial Ovarian Cancer: Recommended Regimens.

Drugs	Dose (mg/m²)*	Route	Interval (weeks)	Treatments (cycles)
Standard Regimens
Intraperitoneal Chemotherapy
Paclitaxel	135	IV	3, day 1	6
Cisplatin	50�100	IP	day 2
Paclitaxel	60	IP	day 8
Intraperitoneal Chemotherapy
Paclitaxel	175	IV	3	6-8
Carboplatin	AUC* = 5-6	IV
Paclitaxel	135	IV	3	6-8
Cisplatin	75	IV
Alternative Drugs**
Docetaxel	75	IV	3
Doxorubicin, liposomal	35-50	IV	3-4
Topotecan	1.0-1.25	IV	1
4.0	IV	3 (daily 3 3-5 days)
Etoposide	50	PO	3, days 14-21

* Except for carboplatin dosing, where AUC -- area under the curve -- dose calculated by using Calvert formula

** Drugs that can be substituted for paclitaxel if hypersensitivity to that drug occurs; the number of treatments administered as tolerated.^{55,56,57,58,59,60,61,62,63,65}

An old technique known as intraperitoneal chemotherapy seems to be making a comeback; this involves placing an anticancer drug directly inside the abdomen. Given that ovarian malignancies have a propensity to spread throughout the abdominal cavity, this technique may achieve a much higher concentration of anti-cancer drugs near the tumor cells than conventional chemotherapy.⁶⁵ In 1996, intraperitoneal cisplatin was shown in more than 500 patients with Stage III disease to be associated with improved survival and lower toxicity, compared with intravenous cisplatin.⁶⁶ A subsequent study demonstrated a significant improvement in progression-free survival in women receiving intravenous carboplatin and paclitaxel as well as intraperitoneal cisplatin;⁶⁷ however, the improvement in overall survival was not statistically significant. The most recent trials of intraperitoneal agents demonstrated an improvement in overall survival in women who received intraperitoneal cisplatin and both intravenous and intraperitoneal paclitaxel, compared with those who received the same drugs intravenously only.

A down-side of intraperitoneal chemotherapy are the complications associated with intraperitoneal catheters, including infection and obstruction.^68,69 Intraperitoneal chemotherapy is currently considered first-line chemotherapy for women with stage III ovarian cancer who have had complete surgical removal of the tumor.

Conclusion
In summary, because it is rarely diagnosed until well advanced, ovarian cancer remains the deadliest of the gynecologic malignancies. Epithelial ovarian cancer is the most common type of ovarian cancer. The best current therapy is surgery followed by conventional intravenous chemotherapy or, in some women, intraperitoneal chemotherapy.

March 2008

Email this article to a friend

References
1. Berman M and Randall-Whitis L. Management of adnexal masses. Obst Gyn. 110: 201-14, 2007. return

2. update ref to 2008 update authors Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin. 58: xxxx return

3. Berek J and Hacker N. Practical Gynecologic Oncology, 4th ed. 2005. return

4. Negri E, Franceschi S, Tzonou A, Booth M, La Vecchia C, Parazzini F et al. Pooled analysis of three European case-control studies of epithelial ovarian cancer: I. Reproductive factors and risk of epithelial ovarian cancer. Int J Cancer 49:50-56, 1991. return

5. Franceschi S, La Vecchia C, Booth M, Tzonou A, Negri E, Parazzini F et al. Pooled analysis of three European case-control studies of epithelial ovarian cancer: II. Age at menarche and menopause. Int J Cancer. 49:57-60, 1991. return

6. Brinton LA, Lamb EJ, Moghissi KS, Scoccia B, Althuis MD, Mabie JE, and Westhoff CL. Ovarian cancer risk after the use of ovulation-stimulating drugs. Obstet Gynecol. 103(6): 1194-203, 2004. return

7. Kashyap S, Moher D, Fung MF and Rosenwaks Z. Assisted reproductive technology and the incidence of ovarian cancer: a meta-analysis. Obstet Gynecol. 103(4): 785-94, 2004. return

8. Mosgaard BJ, Lidegaard O, Kjaer SK, Schou G, and Andersen AN. Infertility, fertility drugs, and invasive ovarian cancer: a case-control study. Fertil Steril. 67(6): 1005-12, 1997. return

9. The reduction in risk of ovarian cancer associated with oral-contraceptive use. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. N Engl J Med. 316(11): 650-5, 1987. return

10. Engeland A, Tretli S, Bjorge T. Height, body mass index, and ovarian cancer: a follow-up of 1.1 million Norwegian women. J Natl Cancer Inst. 95:1244-48, 2003. return

11. Olsen CM, Green AC, Whiteman DC, Sadehgi S, Kolahdooz F, Webb PM. Obesity and the risk of epithelial ovarian cancer: a systematic review and meta-analysis. Eur J Cancer. 43(4): 690-709, 2007. return

12. Whittemore AS, Gong G, Itnyre J. Prevalence and contribution of BRCA-1 mutations in breast cancer and ovarian cancer: results from three U.S. population-based case-control studies of ovarian cancer. Am J Hum Genet. 60(3): 496-504, Mar 1997. return

13. Ford D, Easton DF, Peto J. Estimates of the gene frequency of BRCA-1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet. 57(6): 1457-62, Dec 1995. return

14. King MC, Marks JH, Mandell JB; New York Breast Cancer Study Group. Science. 302(5645): 643-6, Oct 2003. return

15. Narod SA, Risch H, Moslehi R, Dorum A, Neuhausen S, Olsson H, Provencher D, Radice P, Evans G, Bishop S, Brunet J, Ponder BAJ, Klijn JGM. Oral contraceptives and the risk of hereditary ovarian cancer. N Engl J Med, 339(7): 424-428, 1998. return

16. Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B, Murphy J, Ghadirian P, Freidman E, Foulkes WD, Kim-Sing C,Wagner T, Tung N, Couch F, Stoppa-Lvonnet D, Ainsworth P, Daly M, Pasini B, Gershoni-Baruch R, Eng C, Olopade OI, McLennan J, Karlan B, Weitzel J, Sun P, Narod SA; Hereditary Ovarian Cancer Clinical Study Group. JAMA. 296(2): 185-92, 2006. return

17. Goff BA, Mandel L, Muntz HG, Melancon CH. Ovarian carcinoma diagnosis. Cancer. 89(10): 2068-75, Nov 2000. return

18. Goff BA, Mandel LS, Melancon CH and Muntz HG. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA. 291(22): 2705-12, 2004. return

19. Smith LH, Morris CR, Yasmeen S, Parikh-Patel, Cress RD, Romano, PS. Ovarian cancer: can we make the clinical diagnosis earlier? Cancer. 104(7): 1398-207, 2005. return

20. Goff BA, Mandel LS, Drescher CW, Urban N, Gough S, Schurman KM, Patras J, Mahony BS, Andersen MR. Development of an ovarian cancer symptoms index: possibilities for earlier detection. Cancer. 109(2): 221-7, Jan 2007. return

21. Padilla LA, Radosevich DM, Milad MP. Limitations of the pelvic examination for evaluation of the female pelvic organs. Int J Gyn Obst. 88(1): 84-8, 2005. return

22. Van Nagell JR, Higgins RV, Donaldson ES, Gallion HH, Powell DE, Pavlik EJ, Woods CH, Thompson EA. Transvaginal sonography as a screening method for ovarian cancer: a report of the first 1000 cases screened. Cancer. 65(3): 573-7, 1990. return

23. Ekerhovd E, Wienerroith H, Staudach A, Granberg S. Preoperative assessment of unilocular adnexal cysts by transvaginal ultrasonography: a comparison between ultrasonographic morphologic imaging and histopathologic diagnosis. AJOG 184(2): 48-54, 2001. return

24. Ueland FR, DePriest PD, Pavlik EJ, Kryscio RJ, Van Nagell JR. Preoperative differentiation of malignant from benign ovarian tumors: the efficacy of morphology indexing and Doppler flow sonography. Gyn Onc. 91(1): 46-50, 2003. return

25. Cohen LS, Escobar PF, Scharm C, Glimco B, Fishman DA. Three-dimensional power Doppler ultrasound improves the diagnostic accuracy for ovarian cancer prediction. Gyn Onc 82(1): 40-8, 2001. return

26. Modesitt SC, Pavlik EJ, Ueland FR, DePriest PD, Kryscio RJ, van Nagell JR. Risk of malignancy in unilocular ovarian cystic tumors less than 10 centimeters in diameter. Obst Gyn. 102(3): 594-9, 2003. return

27. Malkasian GD, Knapp RC, Lavin PT, Zurawski VR, Podratz KC, Stanhope CR, Mortel R, Berek JS, Bast RC, Ritts RE. Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: discrimination of benign from malignant disease. AJOG. 159(2): 341-6, 1988. return

28. Carlson JK, Skates SJ, Singer DE. Screening for ovarian cancer. Ann Intern Med. 121(2): 124-32, Jul 1994. return

29. Maggino T, Gadducci A, D�Addario V, Pecorelli S, Lissoni A, Stella M, Romagnolo C, Federghini M, Zucca S, Trio D et al. Prospective multicenter study on CA 125 in postmenopausal pelvic masses. Gynecol Oncol. 54(2): 117-23, Aug 1994. return

30. Sehouli J, Akdogan Z, Heinze T, Konsgen D, Stengel D, Mustea A, Lichtenegger W. Preoperative determination of CASA (Cancer Associated Serum Antigen) and CA-125 for the discrimination between benign and malignant pelvic tumor mass: a prospective study. Anticancer Res. 23(2A): 1115-8, Mar-Apr 2003. return

31. Einhorn N, Sjovall K, Knapp RC, Hall P, Scully RE, Bast RC Jr, Zurawski VR Jr. Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstet Gynecol. 80(1): 14-8, Jul 1992. return

32. Bast RC Jr, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, Berkowitz RS, Leavitt T, Griffiths CT, Parker L, Zurawski VR Jr, Knapp RC. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 309(15): 883-7, Oct 1983. return

33. Skates SJ, Menon U, MacDonald N, Rosenthal AN, Oram DH, Knapp RC, Jacobs IJ. Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women. J Clin Oncol. 21(10 Suppl): 206s-210s, May 2003. return

34. Jacobs I, Davies AP, Bridges J, Stabile I, Fay T, Lower A, Grutzinskas JG, Oram D. Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. Brit Med J. 306(6884): 1030-4, Apr 1993. return

35. Schutter EM, Kenemans P, Sohn C, Kristen P, Crombach G, Westermann R, Mobus V, Kaufmann M, Caffier H, Schmidt-Rhode P et al. Diagnostic value of pelvic examination, ultrasound and serum CA 125 in postmenopausal women with a pelvic mass; an international multicenter study. Cancer. 74(4): 1398-406, Aug 1994. return

36. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, Liotta LA. Use of proteomic patterns in serum to identify ovarian cancer. Lancet. 359(9306): 572-7l, Feb 2002. return

37. Sorace JM, Zhan M. A data review and re-assessment of ovarian cancer serum proteomic profiling. BMC Bioinformatics. 4:42, Epub Jun 2003. return

38. Diamandis EP. Analysis of serum proteomic patterns for early cancer diagnosis: drawing attention to potential problems. J Natl Cancer Inst. 96(5): 353-6, Mar 2004. return

39. Chan JK, Kapp DS, Shin JY, Husain A, Teng NN, Berek JS, Osann K, Leiserowitz GS, Cress RD, O�Malley C. Influence of the gynecologic oncologist on the survival of ovarian cancer patients. Obst Gyn. 109(6): 1342-50, 2007. return

40. Heintz AP, Odicino F, Maisonneuve P, Beller U, Benedet JL, Creasman WT, Ngan HY, Sideri M, Pecorelli S. Carcinoma of the ovary. J Epid Biostats. 6(1): 107-38, 2001. return

41. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL and Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 20(5): 1248-59, Mar 2002. return

42. Eisenkop SM, Friedman RL, Wang HJ. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol. 69(2): 103-8, 1998. return

43. Young RC, Decker DG, Wharton JT, Piver MS, Sindelar WF, Edwards BK, Smith JP. Staging laparotomy in early ovarian cancer. JAMA. 250(22): 3072-6, Dec 1983. return

44. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL and Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 20(5): 1248-59, Mar 2002. return

45. Eisenkop SM, Friedman RL, Wang HJ. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol. 69(2): 103-8, 1998. return

46. Young RC, Decker DG, Wharton JT, Piver MS, Sindelar WF, Edwards BK, Smith JP. Staging laparotomy in early ovarian cancer. JAMA. 250(22): 3072-6, Dec 1983. return

47. Ayhan A, Gultekin M, Taskiran C, Salman MC, Celik NY, Yuce K, Usubutun A, Kucukali T. Routine appendectomy in epithelial ovarian carcinoma: is it necessary? Obstet Gynecol. 105(4): 719-24, Apr 2005. return

48. Ramirez PT, Slomovitz BM, McQuinn L, Levenback C, Coleman RL. Role of appendectomy at the time of primary surgery in patients with early-stage ovarian cancer. Gynecol Oncol. 103(3): 888-90, Dec 2006. return

49. Maltaris T, Boehm D, Dittrich R, Seufert R, Koelbl. Reproduction beyond cancer: a message of hope for young women. Gynecol Oncol. 103(3): 1109-21, Dec 2006. return

50. Heaps JM, Neiberg RK, Berek JS. Malignant neoplasms arising in endometriosis. Obstet Gynecol. 75(6): 1023-8, Jun 1990. return

51. Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T, Suzuki M, Sato I, Taguchi K. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer. 88(11): 2583-9, Jun 2000. return

52. Trimble CL, Kosary C, Trimble EL. Long-term survival and patterns of care in women with ovarian tumors of low malignant potential. Gynecol Oncol. 86(1): 34-7, Jul 2002. return

53. Zanetta G, Rota S, Chiari S, Bonazzi C, Bratina G, Mangioni C. Behavior of borderline tumors with particular interest to persistence, recurrence, and progression to invasive carcinoma: a prospective study. J Clin Oncol. 19(10): 2658-64, May 2001. return

54. Twaalfhoven FC, Peters AA, Trimbos JB, Hermans J, Fleuren GJ. The accuracy of frozen section diagnosis of ovarian tumors. Gynecol Oncol. 41(3): 189-92, Jun 1991. return

55. Stewart CJ, Brennan BA, Hammond IG, Leung YC, McCartney AJ. Intraoperative assessment of ovarian tumors: a 5-year review with assessment of discrepant diagnostic cases. Int J Gynecol Pathol. 25(3): 216-22, Jul 2006 return

56. Riedinger JM, Wafflart J, Ricolleau G, Eche N, Larbre H, Basuyau JP, Dalifard I, Hacene K, Pichon MF. CA 125 half-life and CA 125 nadir during induction chemotherapy are independent predictors of epithelial ovarian cancer outcome: results of a French multicentric study. Ann Oncol. 17(8): 1234-8, Aug 2006. return

57. Gadducci A, Zola P, Landoni F, Maggino T, Sartori E, Bergamino T, Cristofani R. Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study. Gynecol Oncol. 58(1): 42-7, Jul 1995. return

58. Thigpen T, Vance R, Puneky L, Khansur T. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials. Gynecol Oncol. 55(3 Pt 2): S97-107, Dec 1994. return

59. Advanced Ovarian Cancer Trialists Group. Chemotherapy in advanced ovarian cancer: an overview of randomized clinical trials. BMJ. 303(6807): 884-93, Oct 1991. return

60. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). Semin Oncol. 23(5 Suppl 12): 40-7, Oct 1996. return

61. Alberts DS, Green S, Hannigan EV, O�Toole R, Stock-Novack D, Anderson P, Surwit EA, Malvlya VK, Nahhas WA, Jolles CJ. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol. 10(5): 706-17, May 1992. return

62. Swenerton K, Jeffrey J, Stuart G, Roy M, Krepart G, Carmichael J, Drouin P, Stanimir R, O�Connell G, Maclean G et al. Cisplatin-cyclophosphamide versus carboplatin cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 10(5): 718-26, May 1992. return

63. Young RC, Walton LA, Ellenberg SS, Homesley HD, Wilbanks GD, Decker DG, Miller A, Park R, Major F Jr. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med. 322(15): 1021-7, Apr 1990. return

64. Trimbos JB, Parmar M, Vergote I, Guthrie D, Bolis G, Colombo N, Vermoken JB, Torri V, Mangioni C, Pecorelli S, Lissoni A, Swart AM; International Collaberative Ovarian Neoplasm 1; European Organisation for Research and Treatment of Cancer Collaberators - Adjuvant ChemotTherapy In Ovarian Neoplasms. International Collaberative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst. 95(2): 105-12, Jan 2003. return

65. Bell J, Brady MF, Young RC, Lage J, Walker JL, Look KY, Rose GS, Spirtos NM; Gynecologic Oncology Group. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 102(3): 432-9, Sep 2006. return

66. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach EM, Baergen R; Gynecologic Oncology Group. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 21(17): 3194-200, Sep 2003. return

67. du Bois A, Luck HJ, Meier W, Adams HP, Mobus V, Costa S, Bauknecht T, Richter B, Warm M, Schroder W, Olbricht S, Nitz U, Jackisch C, Emons G, Wagner U, Kuhn W, Phisterer J; Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer Study Group. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst. 95(17): 1320-9, Sep 2003. return

68. Markman M. Intraperitoneal chemotherapy. Semin Oncol. 18(3): 248-54, Jun 1991. return

69. Alberts DS, Liu PY, Hannigan EV, O�Toole R, Williams SD, Young JA, Franklin EW, Clarke-Pearson DL, Malviya VK, DuBeshter B. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 335(26): 1950-5, Dec 1996. return

70. Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, Wadler S, Sickel J. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel plus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group and Eastern Cooperative Oncology Group. J Clin Oncol. 19(4): 1001-7, Feb 2001. return

71. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA; Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 354(1): 34-43, Jan 2006. return

72. Cannistra SA. Intraperitoneal chemotherapy comes of age. N Engl J Med. 354(1): 77-9, Jan 2006. return

NEWS SEARCH CONTENTS MEDITORIAL ASK DISCUSS REGISTER HELP HOME

© 2008 interMDnet Corporation. All Rights Reserved. PRIVACY POLICY